BNTX - earlier PR: Biontech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan N
BNTX - earlier PR: Biontech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026; Data Highlights Progress Across Pumitamig (BNT327/BMS986545) and Gotistobart (BNT316/ONC-392), As Well As BioNTech’s mRNA-Based Link To Press Release
BNTX - earlier PR: Biontech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026; Data Highlights Progress Across Pumitamig (BNT327/BMS986545) and Gotistobart (BNT316/ONC-392), As Well As BioNTech’s mRNA-Based Link To Press Release